EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Generation and characterization of a CEACAM5 × CDH17 × CD3 tri-specific T-cell engager for colorectal cancer therapy

Jinxiu Hou, Lisha Dong, Tingting Gu, Jiyuan Tian, Chuan Chen, Rui Shen, Chenpeng Su, Xiaoqian Chen, Dandan Liu, Xiao Wang, Yang He, Yongxin Shang und 4 weitere

Antibody Therapeutics · 04.09.2026

DOI: 10.1093/abt/tbag047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 04.09.2026. Verfasst von Jinxiu Hou und 15 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Helixon Biotechnology Co., Earendil Labs.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CEACAM5 and CDH17 are highly co-expressed in certain solid tumors including colorectal cancer (CRC). Current single-target based immunotherapies, such as antibody-drug conjugates (ADC) and T-cell engagers (TCEs), have shown promising efficacy in clinical trials. In this study, we generated a novel tri-specific TCE (tsTCE) targeting CEACAM5, CDH17, and CD3, aiming to enhance tumor-targeting selectivity and therapeutic efficacy.

Methods

Various TCE molecule formats, including 1 + 1 monovalent (CEACAM5 or CDH17 × CD3), 2 + 1 bivalent or biparatopic (CEACAM5 × CEACAM5 × CD3, CDH17 × CDH17 × CD3) and 1 + 1 + 1 tsTCEs (CEACAM5 × CDH17 × CD3) were generated. A lead tsTCE molecule was selected and investigated by antigen binding affinity, cell binding, T-cell-dependent cellular cytotoxicity, and T-cell activation in vitro. In addition, its’ in vivo antitumor efficacy were evaluated in subcutaneous HT55, SW403, and LS174T tumor xenografts in NCG mice engrafted with human PBMCs.

Results

The CEACAM5 × CDH17 × CD3 tsTCE (tsTCE3) possesses a moderate binding affinity to human/cynomolgus CEACAM5 (KD: 51.0 nM / 109 nM), CDH17 (KD: 42.8 nM / 9.26 nM), and human CD3ε (KD: 51.9 nM). The tsTCE3 effectively kills tumor cells with variable expression levels of CEACAM5 and/or CDH17 and induces significant tumor growth inhibition in multiple cell-derived xenograft models. In the CEACAM5-high / CDH17-high HT55 tumor model, tsTCE3 was more efficacious than cibisatamab analogue and a 2 + 1 CEACAM5 × CEACAM5 × CD3 bivalent bispecific TCE, whereas in the LS174T tumor model (CEACAM5-high / CDH17-low) tsTCE3 was more potent than a 2 + 1 CDH17 × CDH17 × CD3 biparatopic TCE molecule. Notably tsTCE3 elicited minimal cytokine release in HT55 xenograft model.

Conclusions

Our tsTCE3 exhibits potent in vitro tumor cell killing and superior in vivo efficacy with a favorable safety profile, supporting its potential as a promising therapeutic agent for the treatment of CEACAM5 / CDH17 positive solid tumors.

Förderung

  • Helixon Biotechnology Co.
  • Earendil Labs

Zitieren

APA

Hou, J., Dong, L., Gu, T., Tian, J., Chen, C., Shen, R., Su, C., Chen, X., Liu, D., Wang, X., He, Y., Shang, Y., Tang, C., Tian, L., Peng, J., & Zhu, Z. (2026). Generation and characterization of a CEACAM5 × CDH17 × CD3 tri-specific T-cell engager for colorectal cancer therapy. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag047

Vancouver

Hou J, Dong L, Gu T, Tian J, Chen C, Shen R, et al. Generation and characterization of a CEACAM5 × CDH17 × CD3 tri-specific T-cell engager for colorectal cancer therapy. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag047

BibTeX
@article{Hou2026,
  author = {Hou, Jinxiu and Dong, Lisha and Gu, Tingting and Tian, Jiyuan and Chen, Chuan and Shen, Rui and Su, Chenpeng and Chen, Xiaoqian and Liu, Dandan and Wang, Xiao and He, Yang and Shang, Yongxin and Tang, Cheng and Tian, Liang and Peng, Jian and Zhu, Zhenping},
  title = {Generation and characterization of a CEACAM5 × CDH17 × CD3 tri-specific T-cell engager for colorectal cancer therapy},
  journal = {Antibody Therapeutics},
  year = {2026},
  doi = {10.1093/abt/tbag047}
}
Kostenlos starten →